Annovis Bio, Inc. (ANVS)
ANVS moved a median of +0.31% 30 minutes after news, and -0.57% by the close. How ANVS actually reacts to news — the realized, point-in-time move the market made, measured across 246 labeled events over the last three years with zero look-ahead.
ANVS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 49% | 244 |
| 30-min | +0.31% | 52% | 246 |
| 60-min | +0.25% | 51% | 246 |
| to close | -0.57% | 43% | 244 |
| Middle 50% of ANVS reactions | -1.83% to +2.68% |
|---|---|
| Median reaction (30-min) | +0.31% |
| Measured reactions | 246 |
Half of all Annovis Bio, Inc. news events land between -1.83% and +2.68% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ANVS reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 15 | -0.68% | 40% | -2.60% |
| Rating reiterations | 42 | +0.99% | 52% | +0.63% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how ANVS ranks against every other measured name →
That’s how ANVS usually reacts — get an email when it moves on news →Email me when ANVS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ANVS's baseline. Nothing else.
Recent ANVS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form DEFA14A Annovis Bio, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.31% | +2.65% | |
| Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease | Press release | GlobeNewswire | +1.54% | -2.31% | |
| Form DEF 14A Annovis Bio, Inc. For: Oct 14 | SEC filing · Form DEF | SEC EDGAR | +1.46% | +3.64% | |
| Annovis to Host Corporate Update Webinar on September 2, 2026 | Press release | GlobeNewswire | +2.27% | +3.41% | |
| Form PRE 14A Annovis Bio, Inc. For: Aug 24 | SEC filing · Form PRE | SEC EDGAR | +2.27% | +3.41% | |
| Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results | Press release | GlobeNewswire | +0.00% | +1.09% | |
| Form 10-Q Annovis Bio, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.49% | -4.92% | |
| Form 8-K Annovis Bio, Inc. For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | +0.49% | -4.92% | |
| Form 8-K Annovis Bio, Inc. For: Jul 07 | SEC filing · Form 8-K | SEC EDGAR | -1.55% | -3.63% | |
| Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease | Press release | GlobeNewswire | +1.79% | -2.04% | |
| Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer | Press release | GlobeNewswire | +0.53% | +2.13% | |
| Form 8-K Annovis Bio, Inc. For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | +1.71% | -0.57% | |
| Annovis Bio Regains NYSE Listing Compliance | Press release | GlobeNewswire | -1.76% | -9.25% | |
| Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants | Press release | GlobeNewswire | +2.56% | +15.91% | |
| Form 8-K Annovis Bio, Inc. For: May 20 | SEC filing · Form 8-K | SEC EDGAR | -2.02% | +8.59% | |
| Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants | Press release | GlobeNewswire | +2.56% | +15.91% | |
| Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | +0.74% | +1.48% | |
| Form 10-Q Annovis Bio, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.53% | -1.91% | |
| Form 8-K Annovis Bio, Inc. For: May 15 | SEC filing · Form 8-K | SEC EDGAR | -0.53% | -1.91% | |
| Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026 | Press release | GlobeNewswire | -0.21% | -5.83% | |
| Form DEF 14A Annovis Bio, Inc. For: Jun 17 | SEC filing · Form DEF | SEC EDGAR | -0.99% | -0.50% | |
| Form DEFA14A Annovis Bio, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.99% | -0.50% | |
| Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio | Press release | GlobeNewswire | +4.23% | -2.12% | |
| Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission | Press release | GlobeNewswire | -1.83% | -3.05% | |
| Form 8-K Annovis Bio, Inc. For: Apr 09 | SEC filing · Form 8-K | SEC EDGAR | -1.83% | -3.05% | |
| Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants | Press release | GlobeNewswire | -2.27% | -18.18% | |
| Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections | Press release | GlobeNewswire | +0.98% | +11.77% | |
| Annovis Publishes Historical Review of Buntanetap in The Scientist | Press release | GlobeNewswire | +0.98% | +9.85% | |
| Form 8-K Annovis Bio, Inc. For: Mar 23 | SEC filing · Form 8-K | SEC EDGAR | -0.46% | -2.27% | |
| Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study | Press release | GlobeNewswire | +1.21% | +7.66% | |
| NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial | Press release | GlobeNewswire | +1.21% | +7.66% | |
| Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results | Press release | GlobeNewswire | +4.53% | +11.42% | |
| Form 8-K Annovis Bio, Inc. For: Mar 16 | SEC filing · Form 8-K | SEC EDGAR | +4.53% | -4.53% | |
| Form 10-K Annovis Bio, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +4.53% | +11.42% | |
| Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference | Press release | GlobeNewswire | -2.62% | -3.37% | |
| Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease | Press release | GlobeNewswire | +0.36% | -2.80% | |
| Form 8-K Annovis Bio, Inc. For: Feb 12 | SEC filing · Form 8-K | SEC EDGAR | +0.36% | -2.80% | |
| Form 8-K Annovis Bio, Inc. For: Jan 28 | SEC filing · Form 8-K | SEC EDGAR | -5.10% | -4.42% | |
| Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients | Press release | GlobeNewswire | -2.45% | -0.81% | |
| Annovis to Host Corporate Update Webinar on January 28, 2026 | Press release | GlobeNewswire | +3.10% | +5.93% | |
| Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group | Press release | GlobeNewswire | +1.49% | +6.90% | |
| Annovis Announces Two Presentations at the CTAD 2025 Conference | Press release | GlobeNewswire | +3.90% | +6.51% | |
| Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study | Press release | GlobeNewswire | +5.98% | +11.96% | |
| Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients | Press release | GlobeNewswire | +2.01% | +27.85% | |
| Form 8-K Annovis Bio, Inc. For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | +0.41% | — | |
| Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results | Press release | GlobeNewswire | +1.61% | +11.98% | |
| Form 10-Q Annovis Bio, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.41% | — | |
| Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program | Press release | GlobeNewswire | -0.81% | -2.93% | |
| Form 8-K Annovis Bio, Inc. For: Oct 26 | SEC filing · Form 8-K | SEC EDGAR | -0.47% | +5.26% | |
| Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules | Press release | GlobeNewswire | +0.95% | +2.38% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ANVS section they belong to.
Where else ANVS is measured.
ANVS earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Annovis Bio, Inc.'s median reaction calculated?
Every labeled ANVS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 246 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of ANVS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ANVS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.